Pasi A Jänne Selected Research

ErbB Receptors (EGF Receptor)

1/2022	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.
1/2022	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
1/2022	EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
1/2022	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
1/2022	Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
11/2021	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
9/2021	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
1/2021	Overcoming therapy resistance in EGFR-mutant lung cancer.
1/2021	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
1/2020	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pasi A Jänne Research Topics

Disease

173	Neoplasms (Cancer) 10/2022 - 12/2003
160	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 05/2002
82	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2003
23	Disease Progression 01/2022 - 05/2004
21	Adenocarcinoma of Lung 01/2020 - 06/2004
11	Mesothelioma 01/2022 - 11/2004
11	Malignant Mesothelioma 12/2016 - 09/2002
10	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2006
8	Diarrhea 06/2022 - 09/2007
8	Epilepsy (Aura) 01/2019 - 04/2016
6	Breast Neoplasms (Breast Cancer) 11/2021 - 07/2006
5	Nausea 01/2021 - 05/2004
4	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 09/2011
4	Neutropenia 01/2022 - 07/2008
4	Exanthema (Rash) 01/2022 - 05/2004
4	Circulating Neoplastic Cells 01/2018 - 02/2011
4	Leukemia 01/2016 - 04/2009
4	Fatigue 01/2014 - 04/2009
4	Carcinoma (Carcinomatosis) 02/2011 - 05/2004
3	Stomatitis 06/2022 - 11/2014
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 12/2003
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2018 - 03/2010
3	Neuroblastoma 10/2018 - 12/2010
3	Pneumonia (Pneumonitis) 04/2016 - 07/2006
3	Adenocarcinoma 06/2012 - 05/2004
3	Carcinogenesis 10/2008 - 10/2005
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2020
2	Thyroid Neoplasms (Thyroid Cancer) 01/2021 - 01/2018
2	Head and Neck Neoplasms (Head and Neck Cancer) 12/2018 - 11/2013

Drug/Important Bio-Agent (IBA)

99	ErbB Receptors (EGF Receptor)IBA 01/2022 - 09/2002
70	Tyrosine Kinase InhibitorsIBA 01/2022 - 05/2005
58	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2021 - 05/2005
43	Gefitinib (Iressa)FDA Link 11/2019 - 05/2004
29	Phosphotransferases (Kinase)IBA 01/2022 - 06/2004
20	osimertinibIBA 06/2022 - 04/2015
20	CrizotinibIBA 01/2021 - 10/2010
19	Pharmaceutical PreparationsIBA 01/2022 - 05/2004
18	Anaplastic Lymphoma KinaseIBA 10/2018 - 07/2008
17	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 05/2004
15	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2015
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2006
13	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2015 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2009
10	Cisplatin (Platino)FDA LinkGeneric 01/2016 - 11/2004
9	PlatinumIBA 01/2022 - 09/2007
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 05/2007
8	Monoclonal AntibodiesIBA 08/2017 - 07/2006
7	LigandsIBA 11/2021 - 10/2005
7	Cell-Free Nucleic AcidsIBA 11/2021 - 03/2014
7	AfatinibIBA 12/2018 - 01/2016
7	Cetuximab (Erbitux)FDA Link 01/2016 - 08/2005
6	AZD 6244IBA 06/2022 - 03/2012
6	Adenosine Triphosphate (ATP)IBA 01/2021 - 12/2009
6	Biological ProductsIBA 01/2018 - 06/2007
6	Docetaxel (Taxotere)FDA Link 01/2017 - 05/2002
6	dacomitinibIBA 01/2017 - 12/2007
5	Carboplatin (JM8)FDA LinkGeneric 01/2015 - 05/2003
5	Gemcitabine FDA Link 01/2014 - 11/2004
5	Pemetrexed (MTA)FDA Link 07/2008 - 07/2005
4	adagrasibIBA 10/2022 - 01/2020
4	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 10/2008
4	trastuzumab deruxtecanIBA 01/2022 - 01/2020
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 06/2004
4	neratinibIBA 01/2020 - 06/2006
4	NivolumabIBA 01/2018 - 01/2016
4	TOR Serine-Threonine KinasesIBA 10/2014 - 08/2007
4	Epidermal Growth Factor (EGF)IBA 04/2014 - 10/2005
3	NucleotidesIBA 01/2022 - 09/2012
3	Mitogen-Activated Protein KinasesIBA 10/2021 - 05/2007
3	Trastuzumab (Herceptin)FDA Link 01/2021 - 07/2006
3	Bevacizumab (Avastin)FDA Link 10/2019 - 08/2008
3	Everolimus FDA Link 01/2018 - 08/2007
3	ParaffinIBA 12/2012 - 02/2006
3	Formaldehyde (Formol)FDA Link 12/2012 - 02/2006
3	Paclitaxel (Taxol)FDA LinkGeneric 06/2012 - 09/2010
3	Insulin (Novolin)FDA Link 04/2012 - 09/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 10/2010 - 11/2005
3	AntibodiesIBA 03/2010 - 01/2003
2	Protein Kinases (Protein Kinase)IBA 01/2022 - 01/2021
2	amivantamab-vmjwIBA 01/2022 - 10/2021
2	human ERBB2 proteinIBA 01/2022 - 01/2021
2	B7-H1 AntigenIBA 01/2022 - 08/2017
2	mobocertinibIBA 12/2021 - 01/2021
2	Messenger RNA (mRNA)IBA 09/2021 - 01/2016
2	Drug CombinationsIBA 03/2021 - 01/2020
2	Circulating Tumor DNAIBA 01/2021 - 03/2016
2	Cysteine (L-Cysteine)FDA Link 01/2021 - 01/2020
2	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2012
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2020
2	pembrolizumabIBA 12/2018 - 10/2017
2	AntigensIBA 12/2018 - 01/2018
2	QuinazolinesIBA 08/2017 - 01/2017
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2017 - 04/2016

Therapy/Procedure

104	Therapeutics 01/2022 - 05/2004
36	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
9	Radiotherapy 10/2019 - 05/2003
6	Immunotherapy 01/2022 - 01/2016
6	Adjuvant Chemotherapy 10/2019 - 11/2004
3	Precision Medicine 01/2018 - 03/2012
3	Aftercare (After-Treatment) 06/2014 - 07/2006